Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.
Companies that have been paying -- and raising -- their dividends for a long time can be particularly good targets in these cases since any corporation capable of sustaining a dividend through good and bad times is likely to have strong fundamentals. Medtronic (MDT 0.85%) and Johnson & Johnson (JNJ 1.18%) are excellent examples along those lines. Here's what investors need to know.
Businesses that can thrive during downturns
During a recession, economic activity declines, the unemployment rate increases, and with people having less money to spend, consumer demand for various products and services decreases. However, some sectors experience recessions differently than others. Defensive ones, like healthcare, tend to perform better than most, since many medical products and services are a matter of life or death. So, these tend to be the last ones consumers want to skimp on during downturns. Medtronic and Johnson & Johnson provide some of these products and services.
NYSE: MDT
Key Data Points
Medtronic is one of the largest medical device companies in the world. Its portfolio spans four main therapeutic areas, including diabetes care, cardiovascular health, medical surgical, and neuroscience. To get even more specific, Medtronic develops and markets products that help treat aneurysms, strokes, and hernias, and provides insulin pumps to diabetes patients. These are among the last things people will want to avoid spending money on if they can help it.
Similarly, Johnson & Johnson has a vast portfolio of drugs across several therapeutic areas, including immunology, oncology, infectious diseases, and neuroscience. Among the company's top-selling products are Tremfya, which treats several conditions, including ulcerative colitis and Crohn's disease, and Darzalex, a therapy for multiple myeloma. Johnson & Johnson also has a robust medtech segment that helps diversify its business. Further, Johnson & Johnson and Medtronic have deep, entrenched footprints in the industry, whether with patients, physicians, or third-party payers.
Though their sales might dip somewhat in recessions, they should still perform relatively well.
Excellent long-term prospects
Medtronic and Johnson & Johnson have strong prospects due to their leadership in an industry that will continue to grow in the long run as the world's population ages. Beyond general trends, these two healthcare giants have made investments that should pay off down the road. Consider the robotic-assisted surgery market that Intuitive Surgical currently dominates. There is massive potential for growth in this field since, as Medtronic pointed out about two years ago, less than 5% of surgeries that can be performed robotically currently are.
Medtronic developed the Hugo system, a robot device that is in use in some countries and is still undergoing clinical trials in the U.S. Johnson & Johnson's grand entrance in this market should be through its Ottava system that is also in studies. This could represent important long-term tailwinds for these two companies, and there are others as well. Medtronic's diabetes care segment, particularly its series of insulin pumps, should be a key growth driver for the foreseeable future.
NYSE: JNJ
Key Data Points
Johnson & Johnson has developed newer medicines that will help drive top-line growth for years. That includes Carvykti, a cancer medicine that first earned approval in the U.S. in 2022. In 2024, Carvykti's revenue was $963 million, an increase of 92.7% compared to the previous fiscal year. Johnson & Johnson and Medtronic should continue developing and marketing newer and better products that will help drive strong financial results for a long time.
Impeccable dividend track records
Medtronic and Johnson & Johnson have been raising their dividends for decades. The former is on a streak of 47 consecutive years of payout increases, while the latter is a Dividend King, with 62 straight years of dividend growth. In the time these healthcare leaders have hiked their payouts, there have been many presidential administrations, healthcare-related regulatory changes, recessions, bear markets, and even a pandemic. They have survived through it all and are still going strong.
So, investors have nothing to fear: Johnson & Johnson and Medtronic are top dividend stocks to buy and hold if a recession hits.
